Paul Capital in $115m drug royalty buyout

Paul Royalty Fund, an affiliate of secondary specialist Paul Capital Partners, will acquire the royalty rights to US sales of insomnia drug Estorra in conjunction with the drug’s US launch.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this